• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Michael Fitzhugh

Articles by Michael Fitzhugh

Roche sees Perjeta addition boost its breast cancer combo

March 3, 2017
By Michael Fitzhugh
Women whose HER2-positive early breast cancers were treated with Genentech Inc.'s Herceptin (trastuzumab) and chemotherapy after surgery saw greater risk reductions for invasive disease recurrence or death when Perjeta (pertuzumab) was added to treatment, a phase III study found.
Read More

Neuroderm sees positive phase II data pump up shares

March 2, 2017
By Michael Fitzhugh
Neuroderm Ltd. shares (NASDAQ: NDRM) climbed 26.6 percent Wednesday to $29.30 on word that a 24-hour regimen of its continuous delivery levodopa/carbidopa (LD/CD) candidate, ND0612H, significantly decreased the amount of time in which Parkinson's disease (PD) patients faced a reemergence of PD symptoms on medication, eliminating it altogether for some patients.
Read More

Accera's NOURISH trial meets a bitter end

March 1, 2017
By Michael Fitzhugh
Accera Inc.'s metabolic-focused Alzheimer's candidate, AC-1204, has foundered in the company's phase III NOURISH AD trial, failing to deliver statistically significant improvements in memory and cognition vs. placebo for people with mild to moderate Alzheimer's disease. A reformulation of the drug between a successful phase II trial and the phase III study yielded suboptimal exposure, contributing to the lack of efficacy, the company said.
Read More

Gilman-led Arrakis lands $38M series A round

Feb. 28, 2017
By Michael Fitzhugh
Arrakis Therapeutics Inc., a company seeking to develop a pipeline of RNA-targeted small molecules for neurology, oncology and rare genetic disorders, has completed a $38 million series A financing. The funds are expected to help it establish its RNA-focused drug discovery platform this year and then bring its most advanced program close to being ready for studies to back its first investigational new drug application.
Read More

Cempra success: Taksta takes ABSSSI to task in phase III trial

Feb. 27, 2017
By Michael Fitzhugh
Cempra Inc. shares (NASDAQ:CEMP) rose 28.6 percent to $4.05 on Friday as the company reported that early clinical responses to its oral antibiotic, Taksta (fusidic acid), proved noninferior to those for Pfizer Inc.’s oral Zyvox (linezolid) during a phase III trial, meeting the primary endpoint.
Read More

PMV Pharma raises $74M series B for p53-focused cancer pipeline

Feb. 24, 2017
By Michael Fitzhugh
PMV Pharmaceuticals Inc., a company developing cancer therapies to restore p53, a protein commonly mutated in tumors, has landed a $74 million series B financing. Topspin Biotech Fund and Euclidean Capital led the round. Orbimed Advisors, Osage University Partners and founding investor Interwest Partners also chipped in after backing the company's $30 million series A financing in 2014.
Read More

Sweet deal for Gilead? Firm snaps up Sarepta's PRV for $125M cash

Feb. 22, 2017
By Michael Fitzhugh
Duchenne muscular dystrophy specialist Sarepta Therapeutics Inc. gained $125 million by selling to Gilead Sciences Inc. an FDA priority review voucher (PRV) won with its approval of Exondys 51 (eteplirsen).
Read More

Tivantinib misses OS endpoint in phase III liver cancer trial

Feb. 22, 2017
By Michael Fitzhugh
The oral c-Met inhibitor tivantinib missed its primary endpoint of improving overall survival vs. placebo in a phase III hepatocellular carcinoma (HCC) study, calling into question the future of the program, licensed by Arqule Inc. to Tokyo-based Daiichi Sankyo Group in December 2008, even as another phase III study of the candidate in Japan progresses. Shares in Arqule (NASDAQ:ARQL) fell 18.4 percent, closing at $1.20 on Friday.
Read More

Tivantinib misses OS endpoint in phase III liver cancer trial

Feb. 21, 2017
By Michael Fitzhugh
The oral c-Met inhibitor tivantinib missed its primary endpoint of improving overall survival vs. placebo in a phase III hepatocellular carcinoma (HCC) study, calling into question the future of the program, licensed by Arqule Inc. to Daiichi Sankyo Group in December 2008, even as another phase III study of the candidate in Japan progresses. Shares in Arqule (NASDAQ:ARQL) fell 18.4 percent, closing at $1.20 on Friday.
Read More

Valeant wins FDA approval for Siliq

Feb. 17, 2017
By Michael Fitzhugh
Valeant Pharmaceuticals International Inc. won a widely anticipated FDA approval for its moderate to severe plaque psoriasis drug, Siliq (brodalumab), complete with an expected black box warning for suicidal ideation and behavior that analysts expect could hamper sales. U.S. availability of the drug, licensed from Astrazeneca plc, is set for the second half of this year. Acceptance of the drug's EMA marketing authorization application arrived in late 2015.
Read More
Previous 1 2 … 115 116 117 118 119 120 121 122 123 … 179 180 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe